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RadiochemotherapyAfter neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer, 15–27% of the patients
experience a pathological complete response (pCR). This observation raises the question as to whether
invasive surgery could be avoided in a selected cohort of patients who obtain a clinical complete response
after preoperative RCT. In this respect, there has been growing interest in functional imaging techniques
to improve clinical response assessment. This systematic review focuses on the role of diffusion-weighted
imaging (DWI) and 18F-ﬂuorodeoxyglucose positron emission tomography/computed tomography
(18F-FDG PET/CT) in the prediction of pCR after RCT for rectal cancer.
A total of 14 publications on DWI and 25 on 18F-FDG PET/CT were retrieved. Pooled analysis of individ-
ual patient data shows both imaging modalities have a low positive predictive value in the prediction of
pCR (mean PPV of 54% and 39% for DWI- and 18F-FDG PET/CT-based parameters respectively). Especially
pre-RCT imaging is unable to predict pCR with overall accuracies of 68–72% for DWI and 44% for 18F-FDG
PET/CT. Qualitative DWI assessment 5–10 weeks after the end of RCT may outperform apparent diffusion
coefﬁcient (ADC)-based DWI-parameters (overall accuracy of 87% vs. 74–78%). Although few data are
available, early changes in FDG-uptake seem promising in the prediction of pCR and the role of
18F-FDG PET/CT during RCT should be further investigated. Quantitative and qualitative 18F-FDG PET/
CT measurements are equally effective in the assessment of pCR after RCT.
The major strength of DWI and 18F-FDG PET/CT lies in the identiﬁcation of non-responders who are not
candidates for organ preservation. Up to now, DWI and 18F-FDG PET/CT are not accurate enough to safely
select patients for organ-sparing strategies. Future research must focus on the integration of functional
imaging with clinical data and molecular biomarkers.
 2014 Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 158–165 This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Neoadjuvant radiochemotherapy (RCT) followed by total meso-
rectal excision (TME) surgery is currently the standard treatment
for locally advanced rectal carcinoma [1–3]. The tumoral response
to this preoperative treatment is very heterogeneous: while
15–27% of the patients achieve a pathological complete response
(pCR), a partial response is seen in 54–75% and others show no
response at all [4]. Patients who achieve a pCR have a favorable
long-term outcome with excellent local control and disease-free
survival regardless of their initial T- and N-stages [4–6]. Retrospec-
tive studies from Brazil have highlighted the ‘wait-and-see’ policy
in such patients [7]. More recent series support the feasibility of
this approach [8,9]. Adopting a non-operative strategy for clinicalcomplete responders will avoid the risks of surgical morbidity
and mortality, and will spare them the need for a stoma [10–12].
However, before a ‘wait-and-see’ policy could be safely imple-
mented, a precise selection of the eligible patients is mandatory.
The gold standard for assessing the tumoral response to preoper-
ative RCT is conventional histopathological analysis. This method,
however, is only applicable in the postoperative setting and
consequently cannot be used for the preoperative selection for an
individualized treatment. Computed tomography (CT), endorectal
ultrasound (EUS) and conventional magnetic resonance imaging
(MRI) have shown to lack accuracy for restaging after RCT [13–16].
In recent years, there has been growing interest in functional imag-
ing techniques to improve clinical response assessment. These
imaging modalities depict the microstructural and metabolic char-
acteristics of the tumor, allowing assessment of treatment-induced
changes before morphological changes become apparent. In this
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cose positron emission tomography/computed tomography (18F-
FDGPET/CT) have emerged as powerful tools in the response predic-
tion before, during and after neoadjuvant RCT for rectal cancer.
DWI is a non-invasive imaging modality, providing functional
information on the microstructure of tissues through the assess-
ment of differences in water proton mobility [17]. Water diffusion
characteristics depend on several factors such as cell density, vas-
cularity, viscosity of the extracellular ﬂuid and cell membrane
integrity. By quantifying these properties as the apparent diffusion
coefﬁcient (ADC), DWI can be used as an imaging biomarker to
monitor and predict tumoral response to RCT [18,19].
18F-FDG PET semi-quantitatively assesses tumor glucose
metabolic activity through changes in FDG-uptake. A decrease in
FDG-uptake after radiotherapy and/or chemotherapy has been cor-
related with pathological response in several tumor types [20–22].
In this systematic review, we collect the current evidence of the
role of DWI and 18F-FDG PET/CT in the prediction of pCR after pre-
operative RCT for locally advanced rectal cancer.Materials and methods
Search strategy and selection criteria
The MEDLINE and Embase databases were searched for the
terms (‘‘rectal cancer’’ AND ‘‘diffusion magnetic resonance imag-
ing’’ AND ‘‘response’’) and for (‘‘rectal cancer’’ AND ‘‘positron emis-
sion tomography’’ AND ‘‘response’’) (29 September 2014) [23].
These initial searches yielded 155 and 222 publications respec-
tively. Only papers published in English, German, and French were
included, resulting in 153 and 216 articles. All titles and abstracts
were screened and only studies reporting on the role of DWI or
18F-FDG PET in the assessment of pCR after RCT for locally
advanced rectal cancer were retained. Reviews, general overview
articles and congress abstracts were excluded. To identify addi-
tional relevant studies, the reference lists of the retrieved studies
were checked manually. A total of 14 relevant DWI and 25 18F-
FDG PET/CT papers were identiﬁed. Selected studies were evalu-
ated for methodological quality using the quality assessment ofFig. 1. Literatudiagnostic accuracy studies (QUADAS) criteria [24]. Literature
selection results are depicted in Fig. 1. A meta-analysis was not
performed due to the wide heterogeneity between the included
studies.Data extraction
We extracted all available data on the performance of following
quantitative DWI parameters: pretreatment ADC (ADCpre), ADC
during RCT (ADCduring), posttreatment ADC (ADCpost), change in
ADC during RCT (DADCduring) and change in ADC after RCT
(DADCpost). Additionally, volumetric data and data on qualitative
DWI assessment were collected. Following 18F-FDG PET/CT param-
eters were retained: the mean and maximum standardized uptake
value (SUV) measured before (SUVmeanpre, SUVmaxpre), during
(SUVmeanduring, SUVmaxduring) and after RCT (SUVmeanpost, SUV-
maxpost). The absolute change in SUVmax (DSUVmax) and the
response indices were also extracted (RI SUVmean, RI SUVmax), as
was the total lesion glycolysis (TLG) and the metabolic tumor vol-
ume (MTV). The visual response score (VRS) was retained as a
qualitative parameter.
Some papers used receiver operating characteristic (ROC) anal-
ysis to calculate cutoff values for the individual response parame-
ters. A ROC curve plots the true positive rate against the false
positive rate at various threshold settings, thereby allowing to cal-
culate optimal cutoff values. If cutoff values were provided, 2  2
contingency tables were constructed and the sensitivity, speciﬁc-
ity, positive and negative predictive values of DWI and 18F-FDG
PET/CT in the prediction of pCR were calculated (Suppl Fig. 1).
We deﬁned the sensitivity for pCR prediction as the fraction of
patients with pCR that is correctly identiﬁed as such by imaging.
The speciﬁcity is the fraction of patients without pCR correctly
identiﬁed as such by DWI or 18F-FDG PET/CT. The positive predic-
tive value (PPV) reﬂects the probability that a complete response
on imaging is conﬁrmed by pathological examination. Conversely,
the negative predictive value (NPV) reﬂects the probability that an
incomplete response on imaging is conﬁrmed by pathology.
Finally, when available, individual patient data (i.e. true positives,
false positives, true negatives and false negatives) were extractedre search.
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PET/CT parameters.Results
Nine papers reported on the role of ADCpre in the prediction of
pCR (Table 1). Three articles found that a low pretreatment ADC
signiﬁcantly correlated with pCR [25–27]. Our group demonstrated
that a pretreatment ADC lower than 1.06  103 mm2/s predicted
pCR with a sensitivity of 100%, speciﬁcity of 86% and overall accu-
racy of 90% [25]. In a larger patient group, Intven et al. found that a
pretreatment ADC lower than 0.97  103 correctly predicted pCR
with an overall accuracy of 81%, but with a sensitivity of only 56%
[27]. Pooled data show ADCpre predicts pCR with a NPV of 90% and
a speciﬁcity of 68%, but with a PPV of only 35%. In a study of 20
patients it was demonstrated that the change in ADC after 10–15
fractions of radiation therapy (DADCduring) was signiﬁcantly corre-
lated with pCR [25]. ROC analysis showed an area under the curve
(AUC) of 100% at a cutoff point of 50%. Volumetric assessment of
DWI prior to RCT has no value in the prediction of pCR, as shown
by three papers [29,33,34].
Seven papers demonstrated that a high ADCpost value signiﬁ-
cantly correlated with pCR (Table 2). In a retrospective analysis
of 40 patients, Kim et al. found that a mean ADCpost > 1.20  103
mm2/s predicted pCR with a sensitivity and overall accuracy of
100% and 85% respectively [35]. The same authors conﬁrmed this
in a larger retrospective study of 76 patients, although the optimal
cutoff increased to 1.30  103 mm2/s [28]. Conversely, Curvo-
Semedo et al. reported a lower ADCpost in patients who achieved
pCR, although this was not signiﬁcant [29]. Four papers found that
an ADC increase of 41–48% was predictive for pCR [25,27,28,31].
Pooled analysis shows a moderate performance of late quantitative
DWI assessment with overall accuracies of 74% and 78% for ADCpost
and DADCpost respectively. In contrast to pre-RCT DWI, volumetric
assessment after RCT might be a valuable tool for pCR prediction
[29,33,34]. Pooled analysis demonstrates that volumetric DWI
measurements after RCT can predict pCR with a sensitivity and
an overall accuracy of 65% and 90%. Relative changes in tumor
volume on DWI can predict pCR with a sensitivity and accuracy
of 83% and 85% respectively.
Four articles demonstrate that late qualitative DWI assessment
can predict pCR with a pooled speciﬁcity of 94% and an overallTable 1
Early pCR prediction with DWI.
Study N pCR
(%)
b-Values (s/mm2), ﬁeld strength DWI
parameter
Lambrecht [25] 20 30 b0-50-100-500-750-1000, 1.5 T ADCpre
Lambrecht [26] 22 27 b0-50-100-500-750-1000, 1.5T ADCpre
Intven [27] 59 15 b0-200-800, 3T ADCpre
Kim [28] 76 14 b0-600-1000, 1.5T ADCpre
Curvo-Semedo
[29]
49 27 b0-500-1000, 1.5T ADCpre
50 28 VDWIpre
Engin [30] 30 30 b50-400-800, 1.5T ADCpre
Lee [31] 38 24 b0-1000 ADCpre
Genovesi [32] 28 36 b0-400-500-600-800-1000, 3T ADCpre
Ha [33] 100 35 b0-150-1000, 1.5T ADCpre
VDWIpre
Lambregts [34] 112 18 b0-25-50-100-300-500-1000-
1100, 1.5T
VDWIpre R1
VDWIpre R2
Pooled data 226 20 ADCpre
274 20 VDWIpre
Acc = accuracy; ADC = apparent diffusion coefﬁcient; DWI = diffusion weighted imagin
pCR = pathologic complete response; PPV = positive predictive value; R = radiologist; Sen
* Cutoff values of ADC are in mm2/s, cutoff values of volumes are in cm3.
 In one patient, ADC measurements were not obtained because the tumor had an entir
 To obtain pooled data, N was multiplied by the number of participating radiologists.accuracy of 87%, thereby outperforming quantitative DWI mea-
surements [30,36–38].
Thirteen papers reported on the performance of SUVmaxpre or
SUVmeanpre in the prediction of pCR (Table 3). Only one article
found a statistically signiﬁcant correlation between a low SUV-
maxpre and pCR [39]. Individual patient data from two studies
demonstrate that SUVmaxpre predicts pCR with a speciﬁcity and
overall accuracy of only 35% and 44% respectively [42,43]. Early
response prediction by 18F-FDG PET/CT during RCT seems more
promising (Table 4). Based on PET data after 10–12 fractions, our
group demonstrated that a RI SUVmax threshold value of 40% cor-
rectly identiﬁed all patients who achieved pCR [26]. Recently,
Goldberg et al. found that only after one week a decrease in SUVmax
of more than 32% could predict the achievement of pCR with a sen-
sitivity of 75% and a speciﬁcity of 100% [46]. Pooled analysis shows
a PPV and overall accuracy of 69% and 88% respectively for SUV
measurements during RCT.
We found 14 articles reporting on posttreatment SUV as a semi-
quantitative parameter for the assessment of pCR (Table 5). SUV-
maxpost tends to be lower in patients without residual tumor cells
than in patients with suboptimal treatment response. Optimal cut-
off points to discriminate patients who achieve pCR from those
who do not, vary between 3.35 and 5.4 [41–45,48,50].
The most studied PET parameter in late response prediction is
the relative change in SUV measured before and after RCT (RI SUV-
maxpost and RI SUVmeanpost). A higher decrease in SUV was found
predictive for pCR by seven authors [26,41,44,45,50–52]. Optimal
cutoff values for RI SUVmaxpost vary from 45.9% to 76%.
In eleven studies, 18F-FDG PET/CT scans were interpreted sub-
jectively by visual inspection. Pooled data show qualitative analy-
sis after RCT is able to assess pCR with a negative predictive value
of 89% and an overall accuracy of 65%, which is comparable to the
quantitative SUV measurements post-RCT. Three articles investi-
gated changes in MTV and TLG as a response parameter, but only
Sun and co-workers found a relative decrease in MTV and TLG after
5–7 weeks signiﬁcantly predictive for pCR [47,49,52].Discussion
In this systematic review, we collect the current evidence of the
role of DWI and 18F-FDG PET/CT in the prediction of pCR before,
during and after RCT for rectal cancer (Fig. 2).Correlation with
pCR
p-
Value
Cutoff* Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Negative 0.003 1.06  103 100 86 75 100 90
Negative 0.002 1.06  103 100 88 75 100 91
Negative 0.01 0.97  103 56 86 42 92 81
Negative 0.4094 0.91  103 82 39 18 93 45
Negative 0.61 0.97  103 39 81 42 78 69
Negative 0.16 12.5 57 78 50 52 72
Positive 0.066
None 0.972
Negative 0.33
Positive 0.484
Positive 0.742
Negative NA 12.5 55 71 29 88 68
Negative NA 12.5 70 78 41 92 77
69 68 35 90 68
61 75 38 89 72
g; N = number of patients; NA = not available; NPV = negative predictive value;
s = sensitivity; Spec = speciﬁcity; T = Tesla; V = volume.
ely mucinous aspect.
Table 2
Late pCR assessment with DWI.
Study N pCR
(%)
b-values (s/mm2), ﬁeld strength DWI parameter Interval RCT-DWI
(weeks)
Correlation with
pCR
p-value Cutoff* Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Quantitative analysis
Lambrecht [25] 20 30 b0-50-100-500-750-1000, 1.5T DADCpost (%) 5–7 Positive 0.0011 48% 100 93 86 100 95
Intven [27] 59 15 b0-200-800, 3T ADCpost 4–8 Positive 0.047
DADCpost (%) Positive <0.001 41% 78 92 64 96 90
Kim [28] 76 14 b0-600-1000, 1.5T ADCpost 4–6 Positive <0.0001 1.30  103 100 85 52 100 87
DADCpost (%) Positive <0.0001 42% 100 71 37 100 75
Curvo-Semedo
[29]
49 27 b0-500-1000, 1.5T ADCpost 6–8 Negative 0.48 1.41  103 46 56 27 74 53
DADCpost (%) Negative 0.96 25.3% 54 64 35 79 61
50 28 VDWIpost Negative <0.001 0.15 79 100 100 92 94
DVpost (%) positive <0.001 97.5% 86 89 75 94 88
Engin [30] 30 30 b50-400-800, 1.5T ADCpost 6 Positive 0.071
Lee [31] 38 24 b0-1000 ADCpost 6 Positive 0.037
DADCpost (%) Positive 0.026
Genovesi [32] 28 36 b0-400-500-600-800-1000, 3T ADCpost 8 Positive 0.003
Ha [33] 100 35 b0-150-1000, 1.5T ADCpost NA Positive <0.001 1.20  103 71 65 52 81 67
VDWIpost Negative <0.001
DVpost (%) Positive <0.001 86.8% 91 80 71 95 84
Lambregts [34] 112 18 b0-25-50-100-300-500-1000-
1100, 1.5T
VDWIpost R1 NA Negative NA 0.15 60 98 86 92 91
VDWIpost R2 Negative NA 0.15 60 92 63 91 87
DVpost (%) R1 Positive NA 97.5% 80 93 73 96 91
DVpost (%) R2 Positive NA 97.5% 70 82 45 93 79
Kim [35] 40 28 b0-1000, 1.5T ADCpost 4–6 Positive <0.0001 1.20  103 100 79 65 100 85
Song [36] 50 12 b0-100-800-1000, 3T ADCpost 6 Positive <0.0001 1.045  103 100 75 35 100 78
Pooled data 315 24 ADCpost 78 72 47 91 74
204 19 DADCpost (%) 80 78 46 94 78
274 20 VDWIpost 65 96 80 92 90
374 24 DVpost (%) 83 86 65 94 85
Qualitative analysis
Engin [30] 30 30 b50-400-800, 1.5T Signal intensity 8 22 100 100 75 77
Song [36] 50 12 b0-100-800-1000, 3T VRS R1 6 33 98 67 92 90
VRS R2 50 91 43 93 86
Lambregts [37] 120 19 b0-1000, 1.5T VRS R1 5–10 56 94 70 89 86
VRS R2 64 90 62 90 84
VRS R3 52 97 81 89 88
Sassen [38] 70 14 b0-300-1100 (n = 59)
b0-500-100 (n = 11), 1.5T
VRS R1 6 70 93 64 95 90
VRS R2 40 98 80 91 90
Pooled data 630⁄ 18 Qualitative
analysis
53 94 68 90 87
Acc = accuracy; ADC = apparent diffusion coefﬁcient; DWI = diffusion weighted imaging; N = number of patients; NA = not available; NPV = negative predictive value;
pCR = pathologic complete response; PPV = positive predictive value; R = radiologist; RCT = radiochemotherapy; Sens = sensitivity; Spec = speciﬁcity; T = Tesla; V = volume;
VRS = visual response score.
* Cutoff values of ADC are in mm2/s, cutoff values of volumes are in cm3.
 In one patient, ADC measurements were not obtained because the tumor had an entirely mucinous aspect.
Table 3
Early pCR prediction with 18F-FDG-PET/CT.
Study N pCR (%) PET parameter Correlation PET and pCR p-Value Cutoff Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Perez [39] 99 7 SUVmaxpre Negative 0.043
Konski [40] 53 30 SUVmaxpre Positive 0.71
Capirci [41] 81 27 SUVmaxpre Positive 0.097 13.9
Palma [42] 50 22 SUVmaxpre Negative 0.149 10.14 46 74 33 83 68
Martoni [43] 80 20 SUVmaxpre Negative NA 27 100 11 20 100 29
Hur [44] 37 35 SUVmaxpre Negative 0.838
Shanmugan [45] 70 26 SUVmaxpre Positive 0.6
Goldberg [46] 19 21 SUVmaxpre Positive 0.617
Guillem [47] 121 21 SUVmaxpre NA n.s.
SUVmeanpre NA n.s.
Kim [48] 151 13 SUVmaxpre Negative 0.064
Lee [49] 81 6 SUVmaxpre Negative 0.675
SUVmeanpre Negative 0.675
Bampo [50] 30 30 SUVmaxpre Negative 0.08
Van Stiphout [51] 114 21 SUVmaxpre Negative 0.29
Pooled data 130 21 SUVmaxpre 78 35 24 86 44
Acc = accuracy; NPV = negative predictive value; N = number of patients; NA = not available; n.s. = not signiﬁcant; pCR = pathologic complete response; PET = positron
emission tomography; PPV = positive predictive value; Sens = sensitivity; Spec = speciﬁcity; SUV = standardized uptake value.
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Table 4
pCR prediction during RCT with 18F-FDG-PET/CT.
Study N pCR (%) PET parameter Correlation PET and pCR Timing PET p-Value Cutoff Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Lambrecht [26] 22 27 RI SUVmaxduring Positive After 10–12 fractions 0.0036 40% 100 75 60 100 82
Goldberg [46] 19 21 SUVmaxduring Positive After 8 days 0.841
RI SUVmaxduring Positive After 8 days 0.046 32% 75 100 100 94 95
Bampo [50] 30 30 SUVmaxduring Negative After 2 weeks 0.32
RI SUVmaxduring Positive 0.23
Pooled data 41 24 RI SUVmaxduring 90 87 69 96 88
Acc = accuracy; NPV = negative predictive value; N = number of patients; pCR = pathologic complete response; PET = positron emission tomography; PPV = positive predictive
value; RCT = radiochemotherapy; RI = response index; Sens = sensitivity; Spec = speciﬁcity; SUV = standardized uptake value.
Table 5
Late pCR assessment with 18F-FDG-PET/CT.
Study N pCR (%) PET parameter Correlation PET and pCR Interval RCT-PET (weeks) p-Value Cutoff Sens
(%)
Spec
(%)
PPV
(%)
NPV
(%)
Acc
(%)
Quantitative analysis
Lambrecht [26] 22 27 RI SUVmaxpost Positive 5 0.013 76% 100 75 60 100 82
Perez [39] 99 7 SUVmaxpost Negative 6 0.23
SUVmaxpost Negative 12 0.15
RI SUVmaxpost Negative 6 0.87
RI SUVmaxpost Negative 12 0.96
Konski [40] 53 30 SUVmaxpost Positive 3–4 0.18
RI SUVmaxpost Positive 5–6 0.08
Capirci [41] 81 27 SUVmaxpost Negative <0.0001 5.2
RI SUVmaxpost Positive <0.0001 45.90%
DSUVmax Positive 0.296 6.4
Palma [42] 50 22 SUVmaxpost Negative 5–7 0.013 4.07 64 74 41 88 72
RI SUVmaxpost Positive 0.354 69.67% 46 74 33 83 68
DSUVmax Negative 0.594
Martoni [43] 80 20 SUVmaxpost Negative 6–7 NA 5 88 34 25 90 45
RI SUVmaxpost Positive NA 66.10% 94 31 25 95 44
Hur [44] 37 35 SUVmaxpost Negative 4 <0.001 3.35 85 79 69 91 81
RI SUVmaxpost Positive 0.009 75.00% 69 83 69 83 78
DSUVmax Positive 0.404
Shanmugan [45] 70 26 SUVmaxpost Negative 4 0.01 4 78 58 39 88 63
RI SUVmaxpost Positive 0.002 63.00% 83 60 42 91 66
Guillem [47] 121 21 RI SUVmaxpost NA 4–6 n.s.
RI SUVmeanpost NA n.s.
Kim [48] 151 13 SUVmaxpost Negative 5–7 <0.001 3.55 74 64 23 94 65
RI SUVmaxpost Positive 0.19
DSUVmax Negative 0.312
Bampo [50] 30 30 SUVmaxpost Negative 6 0.01 5.4 100 81 69 100 87
RI SUVmaxpost Positive 0.035
Van Stiphout [51] 114 21 SUVmaxpost Negative <0.001
RI SUVmaxpost Positive <0.001
Sun [52] 35 31 RI SUVmaxpost Positive 1 0.932
RI SUVmaxpost Positive 5–7 0.045
RI SUVmeanpost Positive 1 0.444
RI SUVmeanpost Positive 5–7 0.019
Huh [53] 181 14 RI SUVmaxpost Positive 5 NA 63.60% 73 65 26 94 66
Pooled data 418 21 SUVmaxpost 80 61 35 92 65
440 20 RI SUVmaxpost 77 60 42 91 64
Qualitative analysis
Lambrecht [26] 22 27 VRS 5 50 88 60 82 77
Song [36] 50 12 VRS 6 83 43 17 95 48
Guillem [47] 121 21 VRS 4–6 54 66 30 84 64
Capirci [54] 81 35 VRS 4 79 45 43 80 57
Kalff [55] 30 20 VRS 3–4 83 50 29 92 57
Vliegen [56] 20 10 VRS 6.3 50 94 50 94 90
Kristiansen [57] 30 27 VRS 7 75 46 33 83 53
Kalff [58] 63 16 VRS 4–5 80 62 29 94 65
Cho [59] 30 13 VRS 6 75 85 43 96 83
Mak [60] 20 35 VRS 3–6 71 85 71 85 80
Murcia Duréndez [61] 41 20 VRS 7 100 76 50 100 81
Pooled data 508 22 VRS 72 63 35 89 65
Acc = accuracy; NPV = negative predictive value; N = number of patients; NA = not available; n.s. = not signiﬁcant; pCR = pathologic complete response; PET = positron
emission tomography; PPV = positive predictive value; RCT = radiochemotherapy; RI = response index; Sens = sensitivity; Spec = speciﬁcity; SUV = standardized uptake value;
VRS = visual response score.
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Fig. 2. Overview of the sensitivity and speciﬁcity of DWI and 18F-FDG PET/CT in the prediction of pathological complete response. Solid bars represent DWI-based parameters,
while 18F-FDG PET/CT parameters are depicted by hatched bars. Parameters based on pre-RCT imaging and those based on imaging during or after RCT are depicted on the left
and the right side respectively. Parameters are represented in the order of decreasing sensitivity in the prediction of pathological complete response.
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non-responding patients to a different treatment modality (e.g.
surgery) or to treatment intensiﬁcation (e.g. dose escalation or
addition of targeted agents) [62]. Some authors found that a low
pretreatment ADC was correlated with a good response to treat-
ment. Similar ﬁndings have been reported in brain tumors [63]
and in hepatic metastases of colorectal cancer [64]. The association
between the pretreatment ADC and tumor response is hypothe-
sized to be correlated to the presence of necrotic areas (character-
ized by a high ADC), in which tumor cells are exposed to a more
acidic and hypoxic environment, diminishing the effectiveness of
radiation therapy and chemotherapeutic agents [64,65]. However,
coagulative necrosis without cell liquefaction may not increase
ADC and this might be the reason why tumors do not respond well
to neoadjuvant RCT, although they have a low pretreatment ADC. It
should be stressed however that this hypothesis has not yet been
conﬁrmed by radiological-pathological correlative studies. While
baseline 18F-FDG PET/CT itself has limited value in response pre-
diction, the relative change in SUVmax during RCT seems more
promising. A higher decrease in FDG-uptake represents a smaller
amount of metabolically active tumor cells, indicating response
to treatment.
Response assessment before surgery enables physicians to offer
patients who achieve a clinical complete response less extensive
surgery or even a ‘wait-and-see’ policy. Pooled analysis showed
that qualitative DWI assessment had a higher accuracy in pCR pre-
diction than quantitative analysis (87% vs. 74–78%). However, with
respect to sensitivity, ADC measurements outperformed subjective
visual assessment (78–80% vs. 53%), indicating that quantitative
analysis is more accurate in detecting patients with pCR. Quantita-
tive and qualitative 18F-FDG PET/CT evaluations are equally perfor-
mant in the preoperative assessment of complete response.
Most studies suffer from a retrospective design and a low num-
ber of patients. In an attempt to assess the performance of the dif-
ferent imaging parameters, we pooled the available individual
patient data. Most authors provide cutoff values based on ROC
analysis, which aims at the maximal accuracy of response predic-
tion. However, this maximal accuracy may not necessarily repre-
sent the most desirable clinical parameter. For instance, we
believe a high PPV and speciﬁcity are mandatory if alteration ofthe surgical strategy is considered. A low speciﬁcity and PPV may
correlate with many false positives, corresponding to residual
tumor on pathology whereas the DWI or 18F-FDG PET/CT images
show no evidence of disease. In general, DWI and 18F-FDG PET/CT
had a high NPV in the prediction of pCR, making these functional
imaging techniques potential valuable tools to deselect patients
for a conservative treatment approach. Unfortunately, both imag-
ing modalities lack the speciﬁcity and PPV needed to safely select
patients for a ‘wait-and-see’ policy.
The combination of different functional imaging techniques at
different time points may increase the speciﬁcity for pCR predic-
tion. Our group previously showed that the combination of early
and late RI SUVmaxpost thresholds increased the speciﬁcity in the
prediction of pCR (75% for the individual threshold values vs. 94%
when combined) [26].We also demonstrated that the combination
of 18F-FDG PET/CT with pretreatment DWI may further increase
the speciﬁcity of response assessment. Although this study only
included 22 patients, the combination of different imaging modal-
ities at different time intervals is at least hypothesis-generating
and deserves further investigation. Combined PET/MRI cameras
might make these evaluations logistically less cumbersome. Van
Stiphout et al. demonstrated that the integration of functional
imaging and clinical data might also contribute to the accuracy
of pCR assessment [51]. This group developed and validated a
nomogram for pCR prediction by collecting population-based dat-
abases of 953 patients from 4 different institutes. These databases
were divided into three groups: clinical factors (762 patients), pre-
RCT 18F-FDG PET-CT (151 patients) and post-RCT 18F-FDG PET-CT
(162 patients). The model’s performance was evaluated by ROC
analysis. The AUC increased from 0.68 to 0.86 when post-RCT
PET data were added to the clinical and pre-RCT PET variable set.
The integration of blood and tissue biomarkers appears also useful
in pCR prediction after RCT for rectal cancer [66–68].
The ability of functional imaging to predict pCR is affected by
the interval between the end of RCT, the post-treatment scan and
surgery. In most studies, post-treatment 18F-FDG PET/CT and
DWI scans were performed 4–8 weeks after the end of RCT. A
longer time interval between the end of RCT and surgery has
shown to increase pCR rates [69,70]. However, Perez et al. reported
that not all patients beneﬁt from this prolonged interval [65].
164 Functional imaging and pCR in rectal cancerThese authors showed that the increase between early (1 h) and
late (3 h) SUVmax at 6-weeks 18F-FDG PET/CT scans was a signiﬁ-
cant predictor of poor response. Patients who have such an
increase in SUVmax do not beneﬁt from a longer time interval
between RCT and surgery. It is known that the interpretation of
functional imaging scans during and early after the end of RCT
can be confounded by treatment-induced tissue alterations. This
is especially the case for 18F-FDG PET/CT in which RCT-induced
inﬂammation can cause FDG-uptake.
A number of limitations of this analysis must be recognized.
Most papers report on a limited number of patients, yielding large
95% conﬁdence intervals around the diagnostic accuracy parame-
ters, thereby providing cutoff thresholds that are not sufﬁciently
robust for clinical use. Few papers provided enough data to con-
struct individual 2  2 contingency tables. However, by pooling
individual patient data, we were able to evaluate the performance
of DWI and 18F-FDG PET/CT in a larger patient group. Because of
the heterogeneity within the included studies with respect to
patient selection, neoadjuvant treatment and imaging protocols
and analyses, this pooled analysis should be regarded as an indica-
tor of the general performance of DWI and 18F-FDG PET/CT in the
prediction of pCR. Furthermore, the results on functional imaging
prediction are restricted to monocentric studies conducted in
ultra-specialized centers. Validation and implementation in a
multicenter setting are still awaited. Standardization through pro-
tocols for both image acquisition and data analysis is necessary to
ensure reproducibility of the results and enable widespread
implementation.
In conclusion, data on the role of 18F-FDG PET/CT and DWI in
response prediction before, during and after RCT for locally
advanced rectal cancer are emerging. In general, a low pretreat-
ment ADC, an increase in ADC and decrease in SUV are associated
with better response to RCT. Pooled analysis shows qualitative
DWI assessment 5–10 weeks after the end of RCT outperforms
ADC-based DWI-parameters. Although little data are available,
early changes in FDG-uptake seem promising and the role of
18F-FDG PET/CT during RCT should be further investigated. Multi-
center studies using large patient populations are needed to vali-
date the role of functional imaging in order to identify those
patients who may beneﬁt from a less aggressive therapeutic
approach after RCT. Up to now, DWI and 18F-FDG PET/CT are not
accurate enough to safely select patients for organ preservation.
Future research must focus on the integration of functional
imaging with clinical data and molecular biomarkers.Conﬂict of interest
None declared.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.radonc.2014.11.
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